Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967382 · ClinicalTrials.gov registry record · Phase 3
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
A Phase 3 study of Pregnancy and Pregnancy Complications, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
- 12
- Study locations
NCT00967382: Completed Phase 3 study of Pregnancy and Pregnancy Complications, sponsored by Ottawa Hospital Research Institute.
NCT00967382 is a Phase 3 study of Pregnancy and Pregnancy Complications that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 292 participants, below the 871-participant average among 191 other Pregnancy trials with a reported enrollment target (66% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00967382, a Phase 3 study of Pregnancy and Pregnancy Complications, has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
- 12
- Study locations
Study Summary
The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?
Conditions Studied
Interventions
- DRUG dalteparin sodium
Study Locations (12)
Ontario
- Hamilton Health Sciences Centre - Hamilton
- The Ottawa Hospital, Civic Campus - Ottawa
- Mount Sinai Hospital - Toronto
- Women's College Health Sciences Centre - Toronto
Quebec
- SMBD Jewish General Hospital - Montreal
- St Mary's Hospital Centre - Montreal
- CHA, Hopital Enfant Jesus - Québec
Missouri
- Saint Louis University - St Louis
Utah
- University of Utah Health Sciences Centre - Salt Lake City
Alberta
- Royal Alexandra Hospital - Edmonton
Nova Scotia
- QEII Health Sciences Centre - Halifax
Saskatchewan
- Royal University Hospital - Saskatoon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2000-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
What the finished NCT00967382 record still lists
NCT00967382 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, below the 871-participant average among 191 other Pregnancy trials with a reported enrollment target (66% lower).
The record links to 3 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which dalteparin sodium is the first listed.
NCT00967382 lists 12 locations in 7 states (Ontario, Quebec, Missouri).
Frequently Asked Questions
What is clinical trial NCT00967382 about?
NCT00967382 is a clinical study titled "TIPPS: Thrombophilia in Pregnancy Prophylaxis Study". The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent t...
What is the current status of trial NCT00967382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2000-07. Estimated completion is 2014-03.
What conditions does trial NCT00967382 study?
This clinical trial studies the following conditions: Pregnancy, Pregnancy Complications, Thrombophilia.
What interventions are being tested in trial NCT00967382?
The interventions under investigation include: dalteparin sodium (DRUG).
Who is sponsoring clinical trial NCT00967382?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00967382 being conducted?
This trial has 12 study locations across Missouri, Utah, Alberta, Nova Scotia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00967382's enrollment target sits among peer trials
292 73rd of 191 higher than 119 of 191 other Pregnancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Different Medications to Induce Labor
RECRUITING · Phase 3
-
Ropivacaine and Fentanyl for Labor Epidural Initiation
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
COMPLETED · Phase 3
-
The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants
COMPLETED · Phase 3
-
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia